Main Research Findings 1) Results of this study reported that IGF-1 DES led to excitatory transmission in the CA1 region of the rat hippocampus and enhancement of fEPSP slopes in a dose-dependent manner
5) Given some challenges with accessing GLP-1RAs, e.g., due to shortage in the market, prohibitive costs and other factors, the obesity medicine field has observed an uptake in the prescription of other approved medications for obesity
In fact, long-term medication can cause side-effects, surgery can lead to spinal instability and adjacent segment disease, and recurrence of IVD disease may occur [12]
GLP-1 receptor agonists are a class of medications primarily licensed for the treatment of type 2 diabetes mellitus and, in some formulations, for weight management in adults with obesity or overweight with weight-related comorbidities
Starting dose also mattered for tolerability